Kazutoyo Miura

National Institutes of Health

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Carole A. Long

National Institutes of Health

178

Ababacar Diouf

North Carolina State University

Simon J. Draper

Jenner Institute

Michael P. Fay

National Institutes of Health

Louis H. Miller

National Institute of Allergy and Infectious Diseases

Sarah E. Silk

University of Oxford

Sumi Biswas

University of Oxford

Bingbing Deng

National Institute of Allergy and Infectious Diseases

Angela M. Minassian

University of Oxford

C. Richter King

Program for Appropriate Technology in Health

Cooperative Institutions

National Institutes of Health

245

National Institute of Allergy and Infectious Diseases

228

University of Oxford

209

Jenner Institute

140

Johns Hopkins University

University of Bamako

University of Washington

Université des Sciences, des Techniques et des Technologies de Bamako

Harvard University

London School of Hygiene & Tropical Medicine

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Cross-reactivity of rPvs48/45, a recombinant Plasmodium vivax protein, with sera from Plasmodium falciparum endemic areas of Africa

bioRxiv (Cold Spring Harbor Laboratory) (2024)

Saidou Balam Kazutoyo Miura Imen Ayadi Drissa Konaté Nathan C. Incandela

48/45, a

Cross-reactivity

10.1101/2024.04.10.588966

Cite

Citations (1)

Novel Transmission-Blocking Antimalarials Identified by High-Throughput Screening of Plasmodium berghei Ookluc

Antimicrobial Agents and Chemotherapy (2023)

Juliana Calit Jéssica E. Araújo Bingbing Deng Kazutoyo Miura Xiomara A. Gaitán

Safe and effective malaria transmission-blocking chemotherapeutics would allow a community-level approach to malaria control and eradication efforts by targeting the mosquito sexual stage of the parasite life cycle. However, only a single drug, primaquine, is currently approved for use in reducing transmission, and drug toxicity limits its widespread implementation. To address this limitation in antimalarial chemotherapeutics, we used a recently developed transgenic Plasmodium berghei line, Ookluc, to perform a series of high-throughput

Plasmodium berghei

Primaquine

Plasmodium (life cycle)

Anopheles stephensi

Piperaquine

10.1128/aac.01465-22

Cite

Citations (5)

Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity

PLoS ONE (2019)

Jo-Anne Chan David Wetzel Linda Reiling Kazutoyo Miura Damien R. Drew

The development of effective malaria vaccines remains a global health priority. Currently, the most advanced vaccine, known as RTS,S, has only shown modest efficacy in clinical trials. Thus, the development of more efficacious vaccines by improving the formulation of RTS,S for increased efficacy or to interrupt malaria transmission are urgently needed. The RTS,S vaccine is based on the presentation of a fragment of the sporozoite antigen on the surface of virus-like particles (VLPs) based on human hepatitis B virus (HBV). In this study, we have developed and evaluated a novel VLP platform based on duck HBV (known as Metavax) for malaria vaccine development. This platform can incorporate large and complex proteins into VLPs and is produced in a Hansenula cell line compatible with cGMP vaccine production. Here, we have established the expression of leading P. falciparum malaria vaccine candidates as VLPs. This includes Pfs230 and Pfs25, which are candidate transmission-blocking vaccine antigens. We demonstrated that the VLPs effectively induce antibodies to malaria vaccine candidates with minimal induction of antibodies to the duck-HBV scaffold antigen. Antibodies to Pfs230 also recognised native protein on the surface of gametocytes, and antibodies to both Pfs230 and Pfs25 demonstrated transmission-reducing activity in standard membrane feeding assays. These results establish the potential utility of this VLP platform for malaria vaccines, which may be suitable for the development of multi-component vaccines that achieve high vaccine efficacy and transmission-blocking immunity.

Vaccine efficacy

Attenuated vaccine

10.1371/journal.pone.0221733

Cite

Citations (23)

Overcoming Allelic Specificity by Immunization with Five Allelic Forms of Plasmodium falciparum Apical Membrane Antigen 1

Infection and Immunity (2013)

Kazutoyo Miura Raúl Herrera Ababacar Diouf Hong Zhou Jianbing Mu

Apical membrane antigen 1 (AMA1) is a leading vaccine candidate, but the allelic polymorphism is a stumbling block for vaccine development. We previously showed that a global set of AMA1 haplotypes could be grouped into six genetic populations. Using this information, six recombinant AMA1 proteins representing each population were produced. Rabbits were immunized with either a single recombinant AMA1 protein or mixtures of recombinant AMA1 proteins (mixtures of 4, 5, or 6 AMA1 proteins). Antibody levels were measured by enzyme-linked immunosorbent assay (ELISA), and purified IgG from each rabbit was used for growth inhibition assay (GIA) with 12 different clones of parasites (a total of 108 immunogen-parasite combinations). Levels of antibodies to all six AMA1 proteins were similar when the antibodies were tested against homologous antigens. When the percent inhibitions in GIA were plotted against the number of ELISA units measured with homologous AMA1, all data points followed a sigmoid curve, regardless of the immunogen. In homologous combinations, there were no differences in the percent inhibition between the single-allele and allele mixture groups. However, all allele mixture groups showed significantly higher percent inhibition than the single-allele groups in heterologous combinations. The 5-allele-mixture group showed significantly higher inhibition to heterologous parasites than the 4-allele-mixture group. On the other hand, there was no difference between the 5- and 6-allele-mixture groups. These data indicate that mixtures with a limited number of alleles may cover a majority of the parasite population. In addition, using the data from 72 immunogen-parasite combinations, we mathematically identified 13 amino acid polymorphic sites which significantly impact GIA activities. These results could be a foundation for the rational design of a future AMA1 vaccine.

Apical membrane

10.1128/iai.01414-12

Cite

Citations (45)

Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model

Proceedings of the National Academy of Sciences (2018)

Juliana M. Sá Sarah R. Kaslow Michael Krause Viviana A. Melendez-Muniz Rebecca E. Salzman

Significance Artemisinin-based combination therapies (ACTs) are first-line antimalarial therapies used worldwide. The artemisinin drug (ART) component clears the bulk of infection rapidly, but small numbers of persistent parasites must be removed by the partner drug. Longer parasite clearance t 1/2 values have been associated with a Kelch-propeller mutation (K13 C580Y), raising concerns of increased ART resistance. We investigated effects of C580Y by using a Plasmodium falciparum cross and a monkey malaria model. Following three standard doses of ART, infections with or without the C580Y mutation cleared to microscopically undetectable levels, as in humans; however, frequent recrudescences occurred with both types of infection. These results emphasize the importance of effective partner drugs to kill the parasites that persist through the ART component of ACT.

Clearance

Artesunate

Plasmodium (life cycle)

10.1073/pnas.1813386115

Cite

Citations (51)

Relationship between Malaria Incidence and IgG Levels to Plasmodium falciparum Merozoite Antigens in Malian Children: Impact of Hemoglobins S and C

PLoS ONE (2013)

Kazutoyo Miura Mahamadou Diakité Ababacar Diouf Saibou Doumbia Drissa Konaté

Heterozygous hemoglobin (Hb) AS (sickle-cell trait) and HbAC are hypothesized to protect against Plasmodium falciparum malaria in part by enhancing naturally-acquired immunity to this disease. To investigate this hypothesis, we compared antibody levels to four merozoite antigens from the P. falciparum 3D7 clone (apical membrane antigen 1, AMA1-3D7; merozoite surface protein 1, MSP1-3D7; 175 kDa erythrocyte-binding antigen, EBA175-3D7; and merozoite surface protein 2, MSP2-3D7) in a cohort of 103 HbAA, 73 HbAS and 30 HbAC children aged 3 to 11 years in a malaria-endemic area of Mali. In the 2009 transmission season we found that HbAS, but not HbAC, significantly reduced the risk of malaria compared to HbAA. IgG levels to MSP1 and MSP2 at the start of this transmission season inversely correlated with malaria incidence after adjusting for age and Hb type. However, HbAS children had significantly lower IgG levels to EBA175 and MSP2 compared to HbAA children. On the other hand, HbAC children had similar IgG levels to all four antigens. The parasite growth-inhibitory activity of purified IgG samples did not differ significantly by Hb type. Changes in antigen-specific IgG levels during the 2009 transmission and 2010 dry seasons also did not differ by Hb type, and none of these IgG levels dropped significantly during the dry season. These data suggest that sickle-cell trait does not reduce the risk of malaria by enhancing the acquisition of IgG responses to merozoite antigens.

Sickle cell trait

Merozoite surface protein

10.1371/journal.pone.0060182

Cite

Citations (11)

Novel Transmission-Blocking Antimalarials Identified by High-Throughput Screening of Plasmodium berghei Ookluc

Zenodo (CERN European Organization for Nuclear Research) (2023)

Juliana Calit Jéssica E. Araújo Bingbing Deng Kazutoyo Miura Xiomara A. Gaitán

Plasmodium berghei

Blocking (statistics)

Plasmodium (life cycle)

10.5281/zenodo.8246875

Cite

Citations (0)

Extending the range of Plasmodium falciparum transmission blocking antibodies

Vaccine (2023)

Lacy M. Simons Patricia Ferrer Nita Gombakomba Knashka Underwood Raúl Herrera

Gamete

10.1016/j.vaccine.2023.04.042

Cite

Citations (7)

Comparative assessment of An. gambiae and An. stephensi mosquitoes to determine transmission-reducing activity of antibodies against P. falciparum sexual stage antigens

Parasites & Vectors (2017)

Maarten Eldering Anaïs Bompard Kazutoyo Miura William J. Stone Isabelle Morlais

With the increasing interest in vaccines to interrupt malaria transmission, there is a demand for harmonization of current methods to assess Plasmodium transmission in laboratory settings. Potential vaccine candidates are currently tested in the standard membrane feeding assay (SMFA) that commonly relies on Anopheles stephensi mosquitoes. Other mosquito species including Anopheles gambiae are the dominant malaria vectors for Plasmodium falciparum in sub-Saharan Africa. Using human serum and monoclonal pre-fertilization (anti-Pfs48/45) and post-fertilization (anti-Pfs25) antibodies known to effectively inhibit sporogony, we directly compared SMFA based estimates of transmission-reducing activity (TRA) for An. stephensi and An. gambiae mosquitoes. In the absence of transmission-reducing antibodies, average numbers of oocysts were similar between An. gambiae and An. stephensi. Antibody-mediated TRA was strongly correlated between both mosquito species, and absolute TRA estimates for pre-fertilisation monoclonal antibodies (mAb) showed no significant difference between the two species. TRA estimates for IgG of naturally exposed individuals and partially effective concentrations of anti-Pfs25 mAb were higher for An. stephensi than for An. gambiae. Our findings support the use of An. stephensi in the SMFA for target prioritization. As a vaccine moves through product development, better estimates of TRA and transmission-blocking activity (TBA) may need to be obtained in epidemiologically relevant parasite-species combination.

Anopheles stephensi

Anopheles gambiae

10.1186/s13071-017-2414-z

Cite

Citations (15)

Effect of re-expansion after short-period lung collapse on pulmonary capillary permeability and pro-inflammatory cytokine gene expression in isolated rabbit lungs

British Journal of Anaesthesia (2004)

Tae Funakoshi Yuichi Ishibe Naoto OKAZAKI Kazutoyo Miura Ruijun Liu

Atelectasis

Vascular permeability

10.1093/bja/aeh101

Cite

Citations (76)